2018
DOI: 10.1253/circj.cj-18-0535
|View full text |Cite
|
Sign up to set email alerts
|

Three-Year Clinical Outcomes Associated With Warfarin vs. Direct Oral Anticoagulant Use Among Japanese Patients With Atrial Fibrillation ― Findings From the SAKURA AF Registry ―

Abstract: A high follow-up rate allowed us to obtain reliable data on the status of OAC use and therapeutic outcomes among AF patients in Japan. Warfarin and DOACs appear to yield equivalent 3-year stroke and all-cause mortality rates, but DOACs appear to reduce the risk of major bleeding.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

3
59
1

Year Published

2019
2019
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 59 publications
(63 citation statements)
references
References 20 publications
3
59
1
Order By: Relevance
“…Those for patients aged ≥85 years (41.3% anticoagulated) were 5.1 and 2.0 per 100 person‐years, respectively . In SAKURA‐AF Registry conducted in Japan, 438 patients received apixaban (mean age, 73.2 years; female, 35.8%), and the rates of stroke or systemic embolism and major bleeding were 0.7 and 0.7 at 1 year, and 3.5 and 3.3 at 2 years . Although the events rates should differ by the patient characteristics of each cohort, our results provide features of Japanese elderly AF patients anticoagulated by on‐label dose of apixaban.…”
Section: Discussionmentioning
confidence: 64%
“…Those for patients aged ≥85 years (41.3% anticoagulated) were 5.1 and 2.0 per 100 person‐years, respectively . In SAKURA‐AF Registry conducted in Japan, 438 patients received apixaban (mean age, 73.2 years; female, 35.8%), and the rates of stroke or systemic embolism and major bleeding were 0.7 and 0.7 at 1 year, and 3.5 and 3.3 at 2 years . Although the events rates should differ by the patient characteristics of each cohort, our results provide features of Japanese elderly AF patients anticoagulated by on‐label dose of apixaban.…”
Section: Discussionmentioning
confidence: 64%
“…The SAKURA registry showed no significant differences in the rates of strokes or SEs, major bleeding, and all‐cause mortality for DOAC vs. warfarin users. Under propensity score matching, the incidence of strokes or SEs and all‐cause death remained equivalent, but the incidence of major bleeding was significantly lower among DOAC than warfarin users . In the HAF‐NET registry, the incidence of strokes or SEs was significantly lesser in the DOAC users, but not that for major bleeding.…”
Section: Discussionmentioning
confidence: 64%
“…Under propensity score matching, the incidence of strokes or SEs and all-cause death remained equivalent, but the incidence of major bleeding was significantly lower among DOAC than warfarin users. 25 In the HAF-NET registry, the incidence of strokes or SEs was significantly lesser in the DOAC users, but not that for major bleeding. This discrepancy might be caused by the frequency of the CA history.…”
Section: Impact Of Doacs On Preventing Clinical Eventsmentioning
confidence: 95%
“…In the Fushimi AF registry, strokes/systemic embolisms and major bleeding occurred in 2.6%/year and 1.5%/year of patients with oral anticoagulants, and 2.1%/year and 1.4%/year of patients without oral anticoagulants . The SAKURA AF Registry also showed no significant difference in the rate of the strokes/systemic embolisms and the major bleeding rate between the DOACs and warfarin users (1.2% vs 1.8%/year and 0.5% vs 1.2%/year, respectively) . Furthermore, fewer anticoagulant drugs were used in the patients with a catheter ablation history (anticoagulant use: 71.5% vs 93.6%, P < .001) in the HAF‐NET Registry.…”
mentioning
confidence: 98%
“…Anticoagulant drugs were used in 86% and DOACs in half of the patients with anticoagulants . After the release of the DOACs, two clinical multicenter registry studies on AF were studied in Japan . In the Fushimi AF Registry, where the patients were enrolled in 2011, DOACs were used in only 2.1% and catheter ablation was performed in 5.3% of the enrolled patients.…”
mentioning
confidence: 99%